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The primary purpose of this study was to examine the regulation of prodynorphin peptides by dopaminergic agents in the central nervous 
system. The indirectly acting catecholamine agonist o-amphetamine sulfate (AMPH) and the dopamine receptor antagonist haloperidol (HAL) 
were administered to rats across a variety of treatment schedules and drug doses. The striatum, substantia nigra and hippocampus were dissected 
and examined by radioimmunoassay for 5 different prodynorphin peptides, covering all 3 opioid domains in the prodynorphin precursor: 
dynorphin A(1-8) and dynorphin A(1-17) of the dynorphin A domain, dynorphin B(1-13) of the dynorphin B domain, and a-neo-endorphin 
and fl-neo-endorphin of the neo-endorphin domain. In addition, the proenkephalin peptide Met-enkephalin-arg6-glyT-leu8 (MERGL) was 
examined in the striatum. AMPH administered one hour prior to sacrifice caused a dose-dependent depletion of prodynorphin peptides in both 
the striatum and substantia nigra. In animals treated with AMPH once each day for 7 days and sacrificed 24 h later, a dramatic dose-dependent 
increase in prodynorphin peptides was observed in these brain regions. Animals treated with AMPH once each day for 7 days and sacrificed 
one hour after the final injection showed no changes in prodynorphin peptides. In addition to changes in individual prodynorphin peptides, 
AMPH treatment caused alterations in the relationships between intermediate peptides (dynorphin A(1-17) and a-neo-endorphin) and their 
immediate products (dynorphin A(1-8) and fl-neo-endorphin). AMPH caused no consistent changes in prodynorphin peptides in the 
hippocampus, or in MERGL in the striatum. Taken together these data suggest that acute dopaminergic activation causes depletion of 
dynorphins from striatonigral prodynorphin neurons, presumably due to dopamine-dependent release of these peptides; repeated activation 
causes repeated release, with a rebound increase in biosynthesis. HAL, in contrast to AMPH caused relatively subtle changes in striatonigral 
prodynorphin peptides. Although no significant changes in individual prodynorphin peptides were observed, HAL treatment caused a change 
in the relationship between dynorphin A(1-17) and dynorphin A(1-8), a change opposite in direction to that observed with AMPH treatment. 
As has been previously reported, repeated HAL administration caused a dose-dependent increase in the proenkephalin peptide MERGL. The 
relatively subtle effects of HAL on prodynorphin peptides suggests that tonic dopamine activity is not important in the regulation of striatonigral 
prodynorphin neurons. The potential functional and behavioral significance of the present results are discussed. 
INTRODUCTION 
The dynorphin family is the most recently discovered 
of the endogenous opioid peptides 8'17'29, and is thus less 
well-understood than the pro-opiomelanocortin or pro- 
enkephalin families. This family of peptides is a product 
of  the prodynorphin (Prodyn) precursor which codes for 
3 opioid peptide domains: the neo-endorphin domain 
(Neo Endo) ,  the dynorphin A domain (Dyn A) and the 
dynorphin B domain (Dyn B), each of which contains the 
amino acid sequence for Leu-enkephalin at their N- 
terminus (Tyr-Gly-Gly-Phe-Leu). These domains are 
flanked by pairs of basic amino acid residues (lysine or 
arginine) at which trypsin-like and carboxypeptidase 
B-like action can occur, yielding the opioid peptides 
a -Neo  Endo,  Dyn A(1-17)  and leumorphin, respec- 
tively H. In addition, further cleavage can give rise to 
smaller opioid peptides: fl-Neo Endo from a-Neo 
Endo  39, Dyn A(1-8)  from Dyn A(1-17)  4°'56 and Dyn B 
from leumorphin 29'43. Recent  evidence suggests that 
Leu-enkephalin might also be a product  of the Prodyn 
precursor TM. The Prodyn precursor can thus produce a 
variety of neuroactive opioid peptides. Despite this 
knowledge of the Prodyn precursor and its putative 
products, little is known of the regulation of Prodyn 
systems in the brain, including which particular products 
are released and how these systems might respond to 
various challenges. 
The nigrostriatal-striatonigral system is one of the 
most widely studied neural systems in the brain and is 
consequently relatively well understood in terms of 
anatomy, physiology, pharmacology and behavior 12't9'47. 
A primary feature of the nigrostriatal system is dopamine 
neurons densely arranged in the substantia nigra pars 
compacta. These neurons have dendrites in the substantia 
nigra pars reticulata and send terminals to the striatum. 
The dopamine terminals in the striatum can innervate 
interneurons within this nucleus, or directly innervate 
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long projection neurons that send terminals back to the 
substantia nigra 32-35. A dense Prodyn projection with cell 
bodies in the striatum and terminals in the substantia 
nigra pars reticulata has been identified 14'38'46'61'65. As 
can readily be seen, this arrangement provides the 
architecture for a nigrostriatal-striatonigral neuronal 
loop whereby dopamine can influence Prodyn neuronal 
activity, and Prodyn peptides can, in return, influence 
dopamine neuron activity. This system therefore provides 
a unique opportunity to study Prodyn expression in the 
brain and its modification by pharmacological manipula- 
tions. 
Although some studies have begun to examine the 
regulation of striatonigral Prodyn peptides by dopamin- 
ergic agents, these studies have been somewhat limited in 
their analyses. First, most published studies to date have 
used limited drug doses and/or injection schedules and 
have thus provided little information about the pharma- 
cology of the drug effects. Second, these studies have 
typically examined only a single prodynorphin peptide 
(using antisera directed against either Dyn A(1-8),  Dyn 
A(1-17) or Dyn B) thus offering little insight into 
possible changes in processing associated with drug 
treatments, and raising the possibility that different 
Prodyn domains may respond differently to dopaminergic 
treatment. To date there appears to be consensus that 
repeated administration of dopamine agonists will in- 
crease content of striatonigral Prodyn peptides 22'36'48. In 
contrast, there is disagreement over the effects of 
dopamine antagonists. While some investigators have 
reported increases in peptide content following repeated 
treatment with antagonists 51, others have reported slight 
decreases 45, or n o  effects 36'48. 
In the present study we examined the effects of acute 
and repeated amphetamine or haloperidol injections on 
Prodyn peptides in the striatum and substantia nigra. 
Amphetamine is an indirect acting catecholamine agon- 
ist, which stimulates release of catecholamines, blocks 
their reuptake, and inhibits the metabolic enzyme mono- 
amine oxidase. Although amphetamine has important 
actions on both dopamine and norepinephrine neurons, 
norepinephrine is much less concentrated than dopamine 
in the striatum (see ref. 19), and appears to play an 
insignificant role in amphetamine-induced effects in the 
nigrostriatal system (see refs. 31, 42). Haloperidol is a 
competitive dopamine receptor antagonist. Our primary 
purpose was to study the regulation of Prodyn peptides 
in a well-understood CNS system. In addition, we hoped 
to obtain information about the neurochemical actions of 
amphetamine and haloperidol that might be important in 
understanding their behavioral effects. Multiple drug 
doses (1.0, 5.0 and 10 mg/kg for amphetamine, and 0.25, 
0.5, 1.0 and 2.0 mg/kg for haloperidol) and injection 
245 
schedules (acute, chronic with no rest, and chronic with 
rest) were utilized. We were thus able to examine 
dose-response curves as well as acute versus chronic 
effects of drugs. In addition, 5 different prodynorphin 
peptide products were examined by radioimmunoassay, 
encompassing all 3 opioid domains in the prodynorphin 
precursor: Dyn A(1-8) and Dyn A(1-17) of the Dyn A 
domain; Dyn B(1-13) of the Dyn B domain; and a-Neo 
Endo and fl-Neo Endo of the Neo Endo domain. We 
were therefore able to obtain information about the 
striatonigral Prodyn system as a whole, rather than 
focusing on one particular peptide or peptide domain in 
the Prodyn precursor. The hippocampus was examined as 
an anatomical control - -  this brain region is rich in 
Prodyn products, is outside the striatonigral pathway and 
is under little dopaminergic influence. For neurochemical 
comparison Met-enkephalin-arg6-gly7-1eu 8 (MERGL) 
was examined in the striatum - -  this peptide is a product 
of the proenkephalin molecule, is found in high concen- 
trations in the striatum, and is regulated differently than 
prodynorphin. 
Beyond the simple demonstrations of changes in 
peptide levels following pharmacological manipulations, 
very little is known about more specific dynamic issues 
concerning the Prodyn peptides in the striatonigral 
system (or for that matter, in the brain in general). More 
information is necessary to begin to understand the 
regulation of these peptides in the CNS. An important 
feature of the present studies is the examination of both 
Dyn A(1-8) and Dyn A(1-17), and both fl-Neo Endo 
and a-Neo Endo. Dyn A(1-17) can be viewed as the 
immediate precursor of Dyn A(1-8),  and a-Neo Endo 
can be viewed as the immediate precursor of fl-Neo 
Endo. Alterations in these 'precursor-product'  relation- 
ships can give valuable information about the dynamic 
status of the Prodyn system, including clues about 
changes in biosynthesis, processing or release. 
MATERIALS AND METHODS 
Animals. Adult male Sprague-Dawley rats were used for all 
experiments. Animals were housed in groups of 5-7 in stainless steel 
cages on a 12-h light/dark cycle. Food and water was available ad 
libitum. 
Experimental design. Animals (5-7 per group) were weighed each 
day of the experiment and drug or vehicle was injected subcutane- 
ously (s.c.) or intraperitoneally (i.p.). In the first series of 
experiments animals were treated s.c. with 1 ml/kg of 0.9% saline, 
or D-amphetamine sulfate (Sigma Chemical Co.) dissolved in saline. 
In these experiments 3 different injection schedules were used: 
acute, in which animals were sacrificed 1 h after a single injection 
of drug or vehicle; 7 days-no rest, in which animals were given a 
single injection each day for 7 days and sacrificed 1 h after the final 
injection; and 7 days with rest, in which animals were given a single 
injection each day for 7 days and sacrificed 24 h after the final 
injection. In the second series of experiments animals were treated 
with Haldol (McNeil Pharmaceutical) or bacteriostatic water for 
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injection, USP (Invenex Laboratories). The injection schedules 
used in these experiments included: acute, as described above; 4 
days-no rest, in which animals received a single i.p. injection each 
day for 4 days and were sacrificed 1 h after the final injection; 4 days 
with rest, in which animals received a single i.p. injection each day 
for 4 days and were sacrificed 24 h after the final injection; and 15 
days with rest, in which animals received a single s.c. injection each 
day for 15 days and were sacrificed 24 h after the final injection. 
Injections were performed at the same time each morning, 
counterbalancing the various groups to minimize circadian influ- 
ences. Following the appropriate treatment rats were sacrificed by 
decapitation and the striatum, substantia nigra and hippocampus 
rapidly dissected on ice. Tissue was immediately frozen on dry ice 
and kept at -80 °C until further processed. 
Extraction of tissue. For extraction of peptides, frozen tissue from 
individual animals was quickly weighed and then homogenized in 1 
ml of ice-cold methanol:0.1 N HC1 (MeOH: HCI; 1:1 v/v) with a 
Brinkman Polytron, The Polytron was washed with 1 ml of ice-cold 
MeOH:HCI and the wash added to the homogenate. The suspended 
tissue was centrifuged for 20 min at 15,000 rpm, the pellet discarded, 
and the supernatant dried under vacuum (Savant Speed Vac). The 
dried extract was redissolved in 1 ml of MeOH:HCI and aliquots 
diluted to appropriate concentrations for radioimmunoassay. Sam- 
ples were stored at -20 °C until assayed. 
Gel chromatography. Gel filtration chromatography was per- 
formed on selected experimental and control groups. A 250-/,1 
aliquot was taken from the extracted sample of each animal, pooled 
according to experimental group, lyophilized, and resuspended in 
1.5 ml of 1% formic acid with 0.01% bovine serum albumin 
(FA/BSA). A 250-~1 aliquot was taken from the pooled samples and 
the remaining 1.25 ml applied to a Sephadex G-50-50 (Sigma 
Chemical Co.) superfine column (1.5 × 90 cm, Pharmacia). The 
column was eluted with FA/BSA and collected in 2-ml fractions. 
Fractions and pooled sample aliquots were lyophilized and resus- 
pended in MeOH:HC1 to appropriate concentration for radioim- 
munoassay. The gel filtration column was calibrated with blue 
dextran for determination of the void volume (mw > 2,000 kDa), 
cobalt chloride for determination of the total volume (row = 0.1 
kDa), and bovine a-lactalbumin (mw = 14.2 kDa), bovine lung 
aprotinin (mw = 6.5 kDa) and insulin b-chain oxidized (mw = 3.5 
kDa) for molecular weight standards. 
Radioimmunoassays. Radioimmunoassays (RIA's) were carried 
out in sodium phosphate buffer (150 mM, pH 7.3, containing 0.9% 
sodium chloride, 0.1% bovine serum albumin, and 0.01% sodium 
azide), in a total volume of 300/~1 (100 ~tl of tissue sample or peptide 
standard dissolved in MeOH:HCI, 100 #1 of 125I-labeled peptide 
diluted to 10,000 cpm in RIA buffer, and 100/A of antiserum diluted 
to appropriate concentration in RIA buffer). After overnight 
incubation at 4 °C, the reaction was terminated by addition of 0.6 
ml of charcoal slurry (5 g of decolorizing carbon, 300 #g of dextran, 
MW 77,800, and 15 ml of swine serum, in 100 ml of 150 mM sodium 
phosphate buffer, pH 7.3) and centrifuged for 15 rain at 7,000 g. The 
pellet was discarded and the supernatant counted in a TM Analytic 
1290 gamma counter. All assays were performed in triplicate. 
Labeled peptides for radioimmunoassay were prepared by chlo- 
ramine-T-mediated iodination. Iodination mixtures were applied to 
Sep Pak C18 cartridges, washed with 0.1% trifluoroacetic acid 
(TFA), and eluted with 60% acetonitrile in 0.1% TFA. The 
iodinated peptides were then purified by HPLC using a Waters 
/~-Bondapak C18 reverse phase column, eluting with a linear 
gradient of 15-40% acetonitrile in 60 min. Dyn Al l -8 )  was 
purchased from Peninsula Laboratories, Dyn Al l -17)  from Penin- 
sula Laboratories or Bachem, a-Neo Endo from Bachem, and Dyn 
B was a gift from D.H. Coy. Antisera for RIA were raised in our 
laboratory by immunizing rabbits with thyroglobulin-conjugated 
peptides 62, except the fl-Neo Endo antiserum which was a gift from 
C.J. Evans of Stanford University. Dyn Al l -17)  antiserum (#54; 
1:100,000 final dilution in the RIA) was raised against synthetic Dyn 
Al l -17)  and is directed against the COOH-terminus of this peptide. 
The ICso of this assay is approximately 10 fmol/tube. This antiserum 
has less than 0.001% cross-reactivity with l)yn Al l -8 ) ,  l_cu.- 
enkephalin, or ct-Neo Endo. Dyn A(1-8) antiserum (#73; 1:230,000 
final dilution) is directed against the COOH-terminal region of lhc 
molecule. This antiserum has less than 0.00tc4 cross-reactivity with 
Dyn Al l -17) ,  Dyn B or Leu-enkephalin and less than 0.01% 
cross-reactivity with ct-Neo Endo. The IC~c ~ of this assay is 
approximately 6 fmol/tube. Dyn B antiserum (#94; final dilution 
1:50,000) was raised against synthetic Dyn B and is C-terminus- 
directed. This antiserum is approximately I).002% cross-reactive 
with Dyn A(1-8), less than 0.001% cross-reactive with Dyn Al l -17)  
or a-Neo Endo, and has an lCso of approximately t5 fmol/tube. 
u-Neo Endo antiserum (#59; l:27,000 final dilution) is COOH- 
terminus directed, has 0. 1% cross-reactivity with fl-Neo Endo, less 
than 0.001% cross-reactivity with Dyn Al l -g ) ,  Dyn Al l -17) ,  Dyn 
B and Leu-enkephalin, and has an IC50 of 8(I fmol/tubc, fl-Neo 
Endo antiserum (C.J. Evans; 1:12,001) final dilution) has less than 
0.01% cross-reactivity with a-Neo Endo, no detectable cross- 
reactivities Dyn Al l -8 ) ,  Dyn Al l -17) ,  Leu-enkephalin, or Met- 
enkephalin, and an ICs0 of approximately 6 fmol/tube. MERGL 
antiserum (#55; 1:1000 final dilution) has an IC~ o of approximately 
120 fmol/tube. 
Data analysis. For statistical purposes, drug effects were exam- 
ined by analysis of variance, followed by Dunnet's t-test for post-hoc 
analysis. Where appropriate, effects were compared by Student's 
t-test• 'Precursor-product' relationships were determined by divid- 
ing the content of the product (Dyn A l l - 8 )  or fi-Neo Endo) by the 
content of the intermediate peptide (Dyn A( 1-17) or a-Neo Endo) 
for each animal and determining the mean and standard error for 
the group. 
RESULTS 
Effects of acute amphetamine injection on Prodyn 
peptides. A n i m a l s  sacr i f i ced  1 h fo l lowing  a s ingle  
i n j e c t i o n  of  a m p h e t a m i n e  (1.0,  5 .0  or  10.0 mg /kg)  
s h o w e d  d o s e - d e p e n d e n t  c h a n g e s  in c o n t e n t  of  all 5 
P r o d y n  p e p t i d e s  w h e n  c o m p a r e d  wi th  sa l ine  con t ro l  
[ ]  DYN A 1-8 
120 [ ]  DYN A 1-17 
i D,'NB 
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Fig. 1. Acute amphetamine causes dose-dependent depletion of 
striatal prodynorphin peptides. Saline (SAL) or D-amphetamine 
sulphate (AM; 1.0, 5.0 or 10 mg/kg) was administered l h prior to 
sacrifice and peptide concentrations were determined by radioim- 
munoassay. Values are expressed as mean percent control + 
S.E.M., n = 6 animals per treatment. Significant differences from 
saline control were determined by analysis of variance followed by 
Dunnet's t-test for post-hoe comparisons: *P < 0.05, **P < 0.01, 
• **P < 0.005 different from saline control as revealed by Dunnet 's 
t-test. Similar effects were observed for all 5 prodynorphin peptides 
in the striatum, as well as in substantia nigra (see Table I). 
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TABLE I 
Effects of acute amphetamine treatment on peptides in striatum, substantia nigra and hippocampus 
Animals (n = 6 per group) received a single s.c. injection of saline (SAL) or o-amphetamine sulfate (AM; 1.0, 5.0 or 10.0 mg/kg) 1 h prior to 
sacrifice. *P < 0.05, **P < 0.01, ***P < 0.005. Values are expressed as pmol/g wet wt. + S.E.M. Values in parentheses are percent control + 
S.E.M. 
SAL AM1 AM5 AM IO 
Striatum 
Dyn A(1-8) 54.7 + 5.2 47.3 + 3.7 34.0 + 3.0*** 50.1 + 5.0 
(100 + 9.6) (86 + 6.8) (62 + 5.5) (92 + 9.1) 
Dyn A(1-17) 13.9 + 1.2 11.0 + 0.7 10.4 + 1.4 14.9 + 1.4 
(100 + 8.7) (80 + 5.1) (74 + 9.9) (107 _+ 10) 
DynB 33.8 + 3.2 30.0 + 2.2 20.7 + 2.5** 33.2 + 3.8 
(100 + 9.4) (89 + 6.5) (61 + 7.4) (98 + 11.2) 
a-Neo Endo 94.0 + 7.1 84.0 + 6.0 67.2 + 10.3 91.6 + 7.8 
(100 + 7.5) (89 + 6.4) (71 + 11.0) (97 + 8.2) 
fl-Neo Endo 2.0 + 0.25 1.7 + 0.17 1.3 + 0.15 2.0 + 0.30 
(100 + 12.5) (85 _+ 8.4) (67 + 7.7) (101 + 14.8) 
MERGL 244 + 22.5 248 + 8.4 209 + 16.0 247 + 19.8 
(100 + 9.2) (101 + 3.5) (85 + 6.5) (101 + 8.1) 
Substantia nigra 
Dyn A(1-8) 129.3 + 10.8 105.4 + 11.4 111.0 + 12.4 159.7 + 45.0 
(100 + 8.4) (82 + 8.8) (86 + 9.6) (124 + 34.8) 
Dyn A(1-17) 36.6 + 3.4 32.2 + 2.1 33.6 + 2.0 51.0 + 12.0 
(100 + 9.4) (88 + 5.9) (92 + 5.4) (139 + 32.7) 
Dyn B 162.9 + 21.8 141.4 + 12.1 138.0 + 9.9 205.6 + 50.1 
(100 + 13.3) (87 + 7.5) (85 _+ 6.0) (126 + 30.8) 
a-Neo Endo 551 + 26.5 491 + 28.0 519 + 47.2 689 + 111.3 
(100 + 4.8) (89 + 5.0) (94 + 8.5) (125 + 20.1) 
fl-Neo Endo 10.1 + 1.3 8.8 + 1.0 7.4 + 0.9 13.7 + 5.0 
(100 + 13.3) (86.4 + 10.2) (73.4 + 9.1) (135 + 49.1) 
Hippocampus 
Dyn A(1-8) 11.6 + 1.5 12.6 + 1.4 12.6 + 2.2 9.8 + 0.5 
(100 + 12.8) (109 + 11.6) (108 + 18.7) (84 + 4.6) 
Dyn A(1-17) 19.3 + 3.4 19.0 + 3.0 18.8 + 2.7 19.6 + 2.2 
(100 + 17.4) (98 + 15.5) (98 + 14.1) (101 + 11.5) 
DynB 33.6 + 3.2 33.3 + 2.9 30.8 + 4.5 29.0 + 1.9 
(100 + 9.5) (99 + 8.9) (92 + 13.5) (86 + 5.5) 
a-Neo Endo 50.6 + 7.2 46.2 + 6.8 47.4 + 9.6 35.2 + 5.7 
(100 + 14.2) (91 + 13.5) (94 + 19.0) (70 + 11.3) 
an imals .  In  the  s t r ia tum,  a U- shaped  d o s e - r e s p o n s e  was 
obse rved ,  with a p p a r e n t  decreases  occurr ing at 1.0 and  
5.0 mg/kg,  and  no  changes  at 10.0 mg/kg. Analys is  of 
va r iance  revea led  a s ignif icant  effect for D y n  A ( 1 - 8 ) ,  
D y n  A ( 1 - 1 7 )  and  D y n  B (Fig. 1, Table  I). Whi le  changes  
in a - N e o  E n d o  and  f l -Neo E n d o  were similar  in bo th  the 
m a g n i t u d e  and  the pa t t e rn  of response ,  these effects were 
no t  stat ist ically significant.  In  the subs tant ia  nigra a 
s imilar  U - s h a p e d  pa t t e rn  was observed ,  a l though smal ler  
in m a g n i t u d e  and  no t  statistically signif icant  (Table I). No 
effects of acute  a m p h e t a m i n e  were observed  on  any  
P rodyn  pept ide  in the h ippocampus  or  on  M E R G L  in the 
s t r i a tum (Table  I).  
Effects o f  repeated amphetamine injections on Prodyn 
peptides. A n i m a l s  given a single in jec t ion  of amphe t -  
am i ne  (1.0, 5.0 or  10.0 mg/kg) once  per  day for 7 days, 
and  sacrificed 24 h fol lowing the final in jec t ion  (7 
days-rest) ,  showed dramat ic  d o s e - d e p e n d e n t  increases  in 
s t r ia tonigral  P rodyn  pept ides  in compar i son  with sal ine 
control  animals .  Analys i s  of va r iance  revea led  a signifi- 
cant  effect for all P rodyn  pept ides  except  f l -Neo E n d o  in 
the s t r ia tum,  and  for D y n  A ( 1 - 8 ) ,  D y n  A ( 1 - 1 7 )  and  D y n  
B in the subs tan t ia  nigra  (Fig. 2, Table  II) .  No effects of 
repea ted  a m p h e t a m i n e  in jec t ions  were observed  on  any  
P rodyn  pept ide  in the  h i p p o c a m p u s  or  on  M E R G L  in the 
s t r ia tum (Table  II) .  
The  concen t r a t i on  of a - N e o  E n d o  was observed  to be 
cons iderab ly  higher ,  and  the a m p h e t a m i n e  response  
(when  expressed as pe rcen t  cont ro l )  cons iderab ly  smal ler  
than  o ther  P rodyn  pept ides  (Table  II) .  In  o rder  to fur ther  
examine  these f indings,  molecu la r  s ieving on  a G-50 
sephadex  co lumn,  fol lowed by r a d i o i m m u n o a s s a y ,  was 
pe r fo rmed  on  the sal ine and  10 mg/kg groups.  Approx-  
imate ly  90% of  a - N e o  E n d o - i m m u n o r e a c t i v e  mater ia l  
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TABLE II 
Effects of repeated amphetamine treatment on peptides in striatum, substantia nigra and hippocampus 
Animals (n = 6 per group) received a single s.c. injection of saline (SAL), or o-amphetamine sulfate (AM; 1.0, 5.0 or 1.0 mg/kg) once each day for 
7 days and were sacrificed 24 h after the final injection. *P < 0.05, **P < 0.0l, ***P < 0.005. Values are expressed as pmol/g wet wt. +_ S.E.M. 
Values in parentheses are percent control + S.E.M. 
SAL AM1 AM5 AM IO 
Striatum 
Dyn A(1-8) 15.0 + 1.5 17.5 + 2.0 21.0 _+ 2.1 32.3 _+ 6.7** 
(100 + 10.0) (117 + 13.6) (140 + 13.8) (216 _+ 44.5) 
Dyn A(1-17) 2.5 + 0.6 3.6 + 0.9 7.0 + 0.7** 8.1/_+ 1.4"** 
(100 + 25.5) (141 + 33.7) (276 + 26.0) (316 _+ 56.9) 
Dyn B 20.1 + 3.1 34.6 + 8.9 50.6 + 5.2* 56.1 + 9.8*** 
(100 + 15.5) (172 + 44.2) (252 + 25.6) (279 __+ 48.9) 
a-Neo Endo 72.1 + 3.6 76.6 _+ 4.5 100.6 _+ 3.6*** 102.9 _+ 6.5*** 
(100 _+ 4.9) (106 _+ 6.2) (140 + 5.0) (143 _+ 9.0) 
13-Neo Endo 3.7 _+ 0.3 3.7 _+_+ 0.3 4.3 _+ 0.3 4.2 _+ 0.5 
(100 + 7.8) (100 _+ 8.1) (119 _+ 9.1) (113 +_ 13.7) 
MERGL 142 + 10.5 144 + 12.4 161 + 16.0 141 _+ 15.5 
(100 _+ 7.4) (101 _+ 8.8) (114 + 11.3) (100 + 10.9) 
Substantia nigra 
Dyn A(1-8) 38.6 + 7.4 55.7 + 11.3 69.8 + 7.6* 76.9 + 6.5** 
(100 + 19.1) (144 + 29.2) (181 + 19.6) (199 + 17.0) 
Dyn A(1-17) 9.6 + 1.6 16.1 + 2.6 26.0 + 2.4*** 31.6 + 2.5*** 
(100 + 16.5) (167 + 26.9) (269 + 25.4) (327 + 26.1) 
Dyn B 99.0 + 23.1 168.0 + 40.0 214.4 + 32.7* 229.4 ___ 21.7"* 
(100 + 23.4) (170 + 40.4) (217 + 33.0) (232 + 22.0) 
a-Neo Endo 289 + 34.7 414 + 62.1 432 + 31.9 428 + 21.3 
(100 + 12.0) (143 _+ 21.5) (149 + 11.0) (148 + 7.4) 
/3-Neo Endo 19.4 + 1.5 24.4 _+ 2.1 23.9 + 2.2 25.2 +_, 2.1 
(100+ 7.9) (126+ 10.8) (123 _+ 11.3) (130 _+ 10.8) 
Hippocampus 
Dyn A(1-8) 7.2 + 1.4 10.6 + 2.8 9.0 + 1.6 7.5 + 2.0 
(100 + 19.2) (146 + 39.1) (124 + 22.9) (104 + 27.3) 
Dyn A(1-17) 24.4 + 1.9 27.4 + 3.6 28.0 + 2.7 28.9 + 5.6 
(100 + 7.9) (112 + 14.8) (115 + 11.1) (118 + 22.8) 
DynB 28.7 + 2.4 36.1 + 4.3 33.9 + 2.9 29.5 _+ 5.7 
(100 + 8.5) (126 + 15.0) (118 + 10.2) (103 + 19.7) 
a-Neo Endo 43.7 _+ 8.5 54.3 + 7.6 50.5 + 7.7 45.7 + 6.2 
(100 + 19.4) (124 + 17.3) (116 _+ 17.7) (105 + 14.3) 
was recovered ,  with approx imate ly  85% of this mater ia l  
e lu t ing  in a single peak  consis tent  with a - N e o  E n d o  
s tandard .  The  m a g n i t u d e  of  the a m p h e t a m i n e  response  
was found  to be near ly  ident ical  in sieved and  uns ieved  
poo led  samples  (155% and  154% of control ,  respec- 
tively). It therefore  appears  that  the high concen t ra t ion  
and  d imin i shed  effect seen with a - N e o  E n d o  were no t  
due to artifacts in the r a d i o i m m u n o a s s a y  of raw samples.  
A n i m a l s  given a single in jec t ion  of a m p h e t a m i n e  (5.0 
mg/kg) once  per  day for 7 days,  and  sacrificed 1 h 
fol lowing the  f inal  in jec t ion  (7 days-no rest),  showed 
a lmost  no  changes  in P rodyn  pept ides  when  compared  
with sal ine cont ro l  animals .  There  was no  significant  
effect on  any  pept ide  in the s t r ia tum or h ippocampus  as 
revea led  by t-tests; in the subs tan t ia  nigra on ly  Dyn  
A ( 1 - 1 7 )  was increased.  Fig. 3 shows a direct compar i son  
be tween  an imals  sacrificed 1 h and  an imals  sacrificed 24 
h fol lowing 7 days of a m p h e t a m i n e  t r ea tmen t .  The re  was 
a dramat ic  increase  in P r o d y n  pept ides  in bo th  the 
s t r ia tum and  subs tan t ia  nigra  du r ing  the 23 h of rest. 
Significant  differences were  obse rved  be tween  1 h and  24 
h for all P rodyn  pept ides  in the s t r i a tum except  D y n  
A ( 1 - 8 )  (Fig. 3); a l though no  signif icant  differences were 
observed  in the  subs tan t ia  nigra ,  the 24-h t ime poin t  was 
greater  than  the 1-h t ime poin t  for all P rodyn  pept ides  
(data  no t  shown).  
Effects o f  amphetamine on 'precursor-product' rela- 
tionships. T r e a t m e n t  with a m p h e t a m i n e  for 7 days caused 
changes in re la t ionships  b e t w e e n  D y n  A ( 1 - 1 7 )  and  D y n  
A ( 1 - 8 ) ,  and  be tween  a - N e o  E n d o  a n d / 3 - N e o  Endo .  A 
d o s e - d e p e n d e n t  decrease ,  relat ive to sal ine control ,  in 
both  D y n  A ( 1 - 8 ) / D y n  A ( 1 - 1 7 )  a n d / 3 - N e o  E n d o / a - N e o  
E n d o  occurred  in the  s t r ia tonigral  system of animals  
sacrificed 24 h fol lowing the  final a m p h e t a m i n e  in ject ion.  
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Fig. 2. Repeated amphetamine causes dose-dependent increases in 
striatal prodynorphin peptides. Saline (SAL) or o-amphetamine 
sulphate (AM; 1.0, 5.0 or 10 mg/kg) was administered once each day 
for 7 days and animals sacrificed 24 h after the final injection; 
peptide concentrations were determined by radioimmunoassay. 
Values are expressed as mean percent control + S.E.M., n = 6 
animals per treatment. Significant differences from saline control 
were determined by analysis of variance followed by Dunnet's t-test 
for post-hoc comparisons: *P < 0.05, **P < 0.01, ***P < 0.005. 
Similar effects were observed for all 5 prodynorphin peptides in the 
striatum, as well as in substantia nigra (see Table II). 
Analysis  of variance revealed significant changes in the 
substant ia  nigra for Dyn  A ( 1 - 8 ) / D y n  A(1-17) ;  decreases 
were similar in the str iatum; however ,  they did not  
achieve significance (Fig. 4). Al though changes were 
qual i tat ively similar for f l-Neo E n d o / a - N e o  Endo ,  these 
changes did not  achieve significance in ei ther  the str iatum 
or  the substant ia  nigra (Fig. 4). Animals  t rea ted  for 7 
300 '  
200 ¸ 
100 
1-8 1-17 B a.NE bNE 
Fig. 3. Effects of repeated amphetamine administration on striatal 
prodynorphin peptides. Animals received a single injection of 
o-amphetamine sulfate (5.0 mg/kg) each for 7 days and were 
sacrificed 1 h or 24 h after the final injection. Values are expressed 
as mean percent saline control + S.E.M. Significant differences 
between 1 h rest and 24 h rest were determined by Student's t-test: 
*P < 0.05, ***P < 0.005. No significant differences from saline 
control were observed at the 1-h time point. At the 24-h time point, 
dynorphin A(1-17) (1-17), dynorphin B(1-13) (B) and a-neo- 
endorphin (aNE) were all significantly increased above saline 
control values. Dynorphin A(1-8) (1-8) and fl-neo-endorphin 
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Fig. 4. Repeated amphetamine treatment alters 'precursor-product' 
relationships in the striatonigral system. A: changes in 'precursor- 
product' relationships in the dynorphin A (Dyn A) domain. B: 
changes in precursor-product relationships in the neo-endorphin 
(Neo-Endo) domain. 'Precursor-product' relationships were deter- 
mined by dividing content of the product (dynorphin A(1-8) or 
fl-neo-endorphin) by the content of its immediate 'precursor' 
(dynorphin A(1-17) or a-neo-endorphin) for each animal; values 
are expressed as mean + S.E.M. Significant differences from saline 
control were determined by analysis of variance followed by 
Dunnet's t-test for post-hoc comparisons: *P < 0.05. Note that 
although changes were not statistically significant in all cases, the 
changes were dose-dependent and in the same direction (decrease 
in product/precursor value). 
days and sacrificed 1 h following the final amphetamine  
inject ion showed similar decreases  in Dyn A ( 1 - 8 ) / D y n  
A(1 -17 )  and fl-Neo E n d o / a - N e o  Endo  (data  not  shown). 
No consistent changes were observed  in the hippocam- 
pus. Animals  sacrificed 1 h following a single amphet-  
amine inject ion showed slight, but non-significant de- 
creases in Dyn A ( 1 - 8 ) / D y n  A(1 -17 ) ,  but  no consistent 
changes in f l-Neo E n d o / a - N e o  Endo  (data  not  shown). 
Effects of haloperidol injections on Prodyn peptides. 
Haloper ido l - in jec ted  animals showed no consistent 
changes in individual  Prodyn pept ides  in the s tr iatum, the 
substantia  nigra or  the h ippocampus  under  any of  the 
t rea tment  protocols  used (Tables I I I  and IV).  In animals 
t rea ted  for 15 days there  appea red  to be a t rend towards 
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TABLE III 
Effects o f  acute or 4-day haloperidol treatment on peptides in striatum and substantia nigra 
Animals (n = 5-6 per group) received a single s.c. injection of sterile water (VEH) or haloperidol (HAL; 0.25, 1.0 or 2.0 mg/kg) 1 h prior to 
sacrifice (Acute); or one injection each day for 4 days (0.25, 0.5, 1.0 or 2.0 mg/kg) with sacrifice 24 h following the final injection (4-day). There 
were no significant effects on any peptide examined. Values are expressed as pmol/g wet wt. _+ S.E.M. Vaues in parentheses are percent control ± 
S.E.M. 
VEH HAL 0.25 HAL 0.5 HAL  1.0 HAL 2.0 
A cute haloperidol: striatum 
Dyn A(1-8) 35.4 + 2.7 35.3 _+ 3.3 37.8 + 3.3 35.4 + 5.4 
(100 + 7.6) (100 + 9.3) (107 _+ 9.2) (100 + 15.3) 
Dyn A(1-17) 2.0 + 0.3 2.4 _+ 0.4 1.7 ___ 0.4 1.5 + 0.5 
(100 + 15.1) (123 _+ 22.5) (84 _+_ 22.0) (78 + 24.3) 
Dyn A( 1-8)/Dyn A(1-17) 19.1 _+ 2.3 17.4 + 3.2 28.8 + 6.2 29.4 + 6.5 
Substantia nigra 
Dyn A(1-8) 151 + 21.4 170 _+ 11.1 190 _+ 34.1 195 _+ 46.4 
(100 + 14.2) (112 + 7.3) (126 _+ 22.5) (129 + 30.7) 
Dyn A(1-17) 16.3 + 2.5 16.3 _+ 1.0 12.9 + 1.9 17.2 + 5.3 
(100 _+ 15.1) (100 + 6.1) (79 _+ 11.5) (106 + 32.8) 
Dyn A(1-8)/Dyn A(1-17) 11.7 + 4.2 10.6 _+ 0.9 15.0 _+ 2.2 13.9 _+ 3.3 
4-Day haloperidol: striatum 
Dyn A(1-8) 40.0 + 2.2 46.7 + 4.3 39.6 + 1.6 45.3 + 2.2 44.5 + 2.1 
(100 + 5.5) (117 _+ 10.7) (99 + 4.0) (113 + 5.5) (111 + 5.2) 
Dyn A(1-17) 2.8 + 0.5 2.9 _+ 0.4 3.6 + 0.8 3.4 _+ 0.7 3.3 + 0.8 
(100 + 18.3) (103 + 13.8) (126 +_ 27.2) (120 + 23.7) (116 + 27.0) 
Dyn A(1-8)/Dyn A(1-17) 13.2 + 0.9 17.6 + 2.9 13.9 +_ 3.0 16.3 __+_ 3.1 17.4 + 3.5 
Substantia nigra 
Dyn A(1-8) 154 + 25.9 170 + 28.1 169 + 16.3 211 + 39.5 205 _+ 30.0 
(100 + 16.8) (110 + 18.2) (110 + 10.6) (137 + 25.6) (133 _+ 19.5) 
Dyn A(1-17) 13.9 + 2.9 11.7 + 1.5 11.8 + 2.9 18.2 + 4.6 16.1 _+ 2.4 
(100 + 20.8) (84 + 10.8) (85 + 20.9) (131 + 32.9) (115 + 17.5) 
Dyn A(1-8)/Dyn A(1-17) 17.0 + 7.8 14.7 + 4.5 21.1 + 7.3 12.7 + 1.9 13.2 _+ 1.3 
decreases in Dyn A(1-17)  and Dyn B; however, these 
were not statistically significant. Despite the lack of 
significant effect of haloperidol on individual peptides, 
there was a significant increase in Dyn A(1-8) /Dyn 
A(1-17)  in the striatum following 15 days of t reatment 
(Table IV). There were also trends toward increases in 
this index following acute or 4 days treatment with 
haloperidol; however, these did not reach significance 
(Table III). In contrast to individual Prodyn peptides, 
M E R G L  increased dramatically in the striatum of ani- 
mals treated for 15 days with haloperidol (Table IV). 
DISCUSSION 
To briefly summarize the present studies, acute am- 
phetamine,  whether given at the end of 7 days of 
t reatment ,  or in the absence of previous treatment,  
caused depletion of striatonigral Prodyn peptides. Re- 
peated amphetamine administration, on the other hand, 
caused dramatic increases in these peptides. In addition 
to the gross changes in peptide content,  changes in 
'p recursor -product '  relationships were observed follow- 
ing amphetamine treatment.  No significant changes in the 
proenkephalin peptide M E R G L  were seen following 
treatment with amphetamine.  Although no consistent 
changes in individual Prodyn peptides were seen follow- 
ing haloperidol t reatment ,  there was a significant change 
in the relationship between Dyn A(1-8)  and Dyn 
A(1-17).  Dramatic increases in the proenkephalin pep- 
tide M E R G L  were observed following repeated haloper- 
idol injections. All of these actions are discussed in more 
detail below. 
A single, acute injection of amphetamine caused 
dose-dependent  depletions of striatonigral Prodyn pep- 
tides. Although changes were not statistically significant 
for each of the peptides examined,  the similar dose-  
response patterns suggest that these peptides were all 
affected similarly by amphetamine treatment.  These 
depletions suggest that amphetamine causes release of 
peptides from Prodyn neurons in the striatonigral system. 
Although a decrease in peptide content  may be caused by 
either release from the neuron  or by a decrease in 
biosynthesis, the acute nature of the challenge in the 
present study leads us to conclude that amphetamine 
indeed caused release of peptides; it is unlikely that the 
one-hour time span is long enough for changes in 
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TABLE IV 
Effects o f  l 5-day haloperidol treatment on peptides in striatum and substantia nigra 
Animals (n = 6-7 per group) received a single i.p. injection of sterile water (VEH) or haloperidol (HAL; 0.25, 0.5, 1.0 or 2.0 mg/kg) once each 
day for 15 days and were sacrificed 24 h after the final injection. *P < 0.05, **P < 0.025, ***P < 0.01. Values are expressed as pmol/g wet wt. + 
S.E.M. Values in parentheses are percent controls + S.E.M. 
VEH H AL  0.25 HAL  0.5 HAL  1.0 HAL  2.0 
Striatum 
Dyn A(1-8) 39.9 + 1.2 38.4 + 2.0 38.3 + 2.5 47.4 + 5.1 41.6 + 1.7 
(100 + 3.1) (96 + 4.9) (96 + 6.3) (119 + 12.7) (104 + 4.2) 
Dyn A(1-17) 2.5 + 0.2 2.3 + 0.5 1.6 + 0.2 2.2 + 0.2 1.6 + 0.1 
(100 + 7.8) (95 + 19.7) (65 + 8.8) (89 + 8.1) (67 + 5.0) 
Dyn A(1-8)/Dyn A(1-17) 16.9 + 1.7 19.4 + 3.1 26.0 + 3.5* 21.6 + 1.0 25.8 + 1.7" 
MERGL 87.7 + 7.3 105.7 + 11.9 95.9 + 9.0 135.0 + 12.7"* 131.5 + 14.6" 
(100 + 8.3) (120 + 13.5) (109 + 10.3) (154 + 14.5) (150 + 16.7) 
Substantia nigra 
Dyn A(1-8) 106.1 + 8.8 74.9 + 8.9 99.2 + 11.4 120.9 + 14.4 96.6 + 18.9 
(100 + 8.2) (71 _+ 8.4) (93 + 10.7) (114 +_ 13.6) (91 _+ 17.8) 
Dyn A(1-17) 11.6 _+ 0.3 9.7 + 0.4 9.1 + 1.0 10.2 _+ 0.6 10.3 _+ 0.7 
(100 + 2.4) (84 + 3.4) (79 + 8.7) (89 + 5.6) (89 + 5.9) 
Dyn A(1-8)/Dyn A(1-17) 8.2 + 0.5 7.8 + 0.9 9.7 + 0.9 11.1 + 1.2 9.1 + 2.4 
biosynthesis to become manifest as changes in content. 
The fact that no effects were observed in the hippocam- 
pus, a brain region rich in dynorphins but under little 
influence of dopamine,  suggests that the effects of 
amphetamine are selective to the striatonigral system. 
Although decreases in striatonigral Prodyn peptides 
were observed at 1.0 and 5.0 mg/kg, no effect was seen 
at 10.0 mg/kg. This U-shaped dose-response curve is 
both interesting and puzzling; this pattern of dose-  
response is common in behavioral pharmacological ex- 
periments (see ref. 55, pp. 283-337). Since high doses of 
amphetamine induce release of  serotonin in addition to 
catecholamines, and since serotonin can serve as a 
functional antagonist of catecholamines in the striatal 
system (see ref. 42), it is possible that amphetamine's  
action on serotonin neurons serves to interfere with its 
effect on dynorphin release. Regardless of the lack of 
effect of amphetamine at this high dose, the putative 
release of Prodyn peptides at the lower doses is of 
profound interest. 
It is intriguing that amphetamine caused depletion of 
peptides in the Prodyn cell body region (striatum) as well 
as the terminal region (substantia nigra). In considering 
the striatonigral system, one typically thinks of striatal 
cell bodies projecting to and terminating in the substantia 
nigra, without thought to potential local projections of 
this nucleus. In fact, striatonigral Prodyn neurons send 
many local collaterals within the striatum in addition to 
their efferent projections (J. Fallon, personal communi- 
cation). The present data suggest that acute dopamin- 
ergic challenge may cause release of Prodyn peptides 
from local terminals in the striatum, as well as from 
terminals projecting to the substantia nigra. Alterna- 
tively, (or perhaps additionally) depletions in the stri- 
atum may have resulted from an increased transport of 
peptides from striatal Prodyn cell bodies to compensate 
for increased amphetamine-dependent  secretion from 
terminals in the substantia nigra. 
Animals injected with amphetamine for 7 days and 
rested for 24 h showed dramatic dose-dependent in- 
creases in all 5 Prodyn peptides in both the striatum and 
substantia nigra. These results are consistent with previ- 
ous observations of  increases in selected Prodyn peptides 
following repeated administration of amphetamine 22'37'48 
or apomorphine 36'37. Increases in peptide content may be 
caused by two contrasting mechanisms: (1) a decrease in 
release from the neuron,  leading to build-up of peptide, 
or (2) an increase in biosynthesis and/or processing. The 
present studies demonstrating depletion of peptide with 
acute amphetamine treatment and increases in peptide 
content following repeated treatment suggest that re- 
peated release of peptides by dopaminergic challenge 
causes a rebound increase in biosynthesis, resulting in 
increased stores in striatonigral neurons, a mechanism 
previously proposed by Li et al. 36'37. This phenomenon is 
particularly well-illustrated in the present study when 
comparing the animals sacrificed 1 h following repeated 
treatment with animals sacrificed 24 h following repeated 
treatment (see Fig. 3). Reflective of a rebound increase 
in biosynthesis, there was a dramatic increase in content 
of striatonigral Prodyn peptides over the 23 h of rest. The 
lack of increase seen in the animals sacrificed at the 1-h 
time point was presumably due to an acute release of 
peptides caused by the latest amphetamine challenge - -  
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these animals would have shown increases had they been 
rested prior to sacrifice. In support of an increase in 
biosynthesis following repeated dopaminergic challenge, 
an increase in striatal Prodyn mRNA has been reported 
following repeated apomorphine treatment 37. However, 
it should be noted that an increase in biosynthesis does 
not rule out the possibility that there might also be a 
concomitant increase in peptide processing following 
repeated dopaminergic challenge. 
Interestingly, although changes occurred in all 5 
Prodyn peptides following amphetamine treatment, the 
changes were not equal in magnitude. In the present 
studies we compared changes in content of two interme- 
diate peptides (Dyn A(1-17) and a-Neo Endo) with their 
respective products (Dyn A(1-8) and fl-Neo Endo), in 
order to assess possible selective changes in release 
and/or processing (for the present purposes Dyn A(1-17) 
can be considered the immediate 'precursor' for Dyn 
A(1-8) and a-Neo Endo the 'precursor' for fl-Neo 
Endo). Treatment with amphetamine for 7 days caused a 
dose-dependent decrease in the ratio of Dyn A(1-8):Dyn 
A(1-17) in both the striatum and the substantia nigra, 
whether animals were sacrificed 1 h or 24 h following the 
final injection. Similar changes were observed in the 
fl-Neo Endo:a-Neo Endo ratio. These changes in the 
precursor-product relationships suggest (1) that Dyn 
A(1-8) and fl-Neo Endo were preferentially released in 
amphetamine-treated animals in comparison to Dyn 
A(1-17) and a-Neo Endo, and/or (2) that the processing 
of Dyn A(1-17) to Dyn A(1-8) and a-Neo Endo to 
fl-Neo Endo was decreased in treated animals. 
In addition to differences in the effects of amphet- 
amine within a particular peptide domain, there were 
apparent differences between domains. In examining the 
percent change in peptide content, it is striking that the 
Neo Endo domain was considerably less responsive than 
the Dyn A domain or the Dyn B domain to repeated 
amphetamine injections. Whereas 7 days of amphet- 
amine (10 mg/kg) increased Dyn A(1-17) and Dyn B 
content in the striatum to approximately 300% of control 
values, this treatment increased a-Neo Endo and fl-Neo 
Endo to only 143% and 113% of control respectively. 
Similar differences in response between these domains 
were observed in the substantia nigra. A second obser- 
vation perhaps pertinent to these findings is that a-Neo 
Endo was found in higher concentrations than the Dyn A 
peptides or Dyn B in the striatum and substantia nigra. 
Molecular sieving of samples verified both the high 
concentration and the diminished response of a-Neo 
Endo to amphetamine. Further, as noted above, the 
fl-Neo Endo response paralleled the a-Neo Endo re- 
sponse, demonstrating that the diminished effect oc- 
curred in both peptide products of the Neo Endo domain. 
These findings suggest that the Neo Endo domain is 
indeed less responsive to repeated amphetamine treat- 
ment than other Prodyn peptide domains, when exam- 
ined as a percent of control values. However, if we 
examine the results as absolute changes in concentration, 
the Neo Endo response appears much closer in magni- 
tude to the responses of the Dyn A domain and the Dyn 
B domain, suggesting that amphetamine may not be 
differentially affecting the different peptide domains; the 
apparent difference in response may have been an 
artifact of examining the results as a percent change in 
the face of the higher content of a-Neo Endo. This then 
raises the question as to why the concentration of a-Neo 
Endo is higher than the Dyn A domain or Dyn B - -  the 
structure of the Prodyn precursor predicts equimolar 
concentrations of these peptide domains. While it is only 
speculation, the most parsimonious explanation for the 
differences in concentration is that Dyn A and Dyn B 
peptides are further processed into Leu-enkephalin, 
while Neo Endo peptides are less likely to be further 
processed. This speculation is enhanced by the fact that 
the putative basic amino acid cleavage signals for pro- 
duction of Leu-enkephalin are identical for Dyn A and 
Dyn B (arginine-arginine) while the putative cleavage 
signal for Neo Endo is different (arginine-lysine). Indeed, 
it has been suggested that the processing enzymes that 
cleave at dibasic residues prefer an arginine-arginine pair 
to an arginine-lysine pair 1 ~. It will be of interest to further 
examine the regulation of the different Prodyn peptide 
products, together with their possible relationship to 
Leu-enkephalin. It should be noted, however, that while 
the study of the processing of Prodyn peptides into 
Leu-enkephalin may be of use in the substantia nigra 64"65, 
the high concentrations of proenkephalin-derived Leu- 
enkephalin in the striatum will interfere with such an 
analysis in this forebrain structure. 
A question that remains insufficiently answered is: Is 
the functional 'tone' of the striatonigral Prodyn system 
altered by repeated amphetamine treatment? The 
changes in peptide content seen in the present experi- 
ments following repeated administration suggest that the 
ratios of releasable products, and therefore the functional 
activity in this system, may indeed be altered by 
treatment with amphetamine. Further, if we examine the 
depletion of Prodyn peptides resulting from an amphet- 
amine challenge, the profile seen in animals sacrificed 1 
h after multiple injections is quite different from the 
profile seen in animals sacrificed 1 h after a single 
injection. When amphetamine was administered to ani- 
mals that had received multiple injections of amphet- 
amine, apparent depletion of total Prodyn immunoreac- 
tivity was not dramatically different from a single 








Fig. 5. Effects of amphetamine challenge on striatal Prodyn pep- 
tides in naive animals and in animals with a history of repeated 
amphetamine injections. The 'Acute' bar represents the amphet- 
amine-dependent depletion of peptides in naive animals that 
received a single injection of amphetamine (content of individual 
peptides in animals that received a single injection of amphetamine, 
5.0 mg/kg, 1 h prior to sacrifice was subtracted from animals that 
received saline). The 'Repeated-Acute' bar represents the amphet- 
amine-dependent depletion of peptides in animals that received 7 
daily injections of amphetamine (content of individual peptides in 
animals that received a single injection of amphetamine, 5.0 mg/kg, 
each day for 7 days and were sacrificed 1 h after the final injection 
was subtracted from animals that received a single injection each 
day for 7 days and were sacrificed 24 h after the final injection). 
Values are expressed as pmol/g wet weight depletion. 
seen following a single injection, and the depletion of 
Dyn A(1-8) was one-fourth that seen following a single 
injection (Fig. 5). Thus, reflecting the different changes 
in content of the different Prodyn peptides, there may be 
a relative increase in the depletion of Dyn B and a 
relative decrease in the depletion of Dyn A(1-8) in 
animals with a previous history of repeated amphetamine 
treatment. The relatively greater r-receptor affinity of 
Dyn B 9 suggests that the striatonigral system will receive 
much greater kappa activation on amphetamine chal- 
lenge following repeated injections of amphetamine than 
following a single, acute injection. Experiments are 
presently underway to more specifically examine whether 
changes in released products occur following repeated 
administration of amphetamine. 
Although there is no direct evidence in the present 
study that the effects of amphetamine are mediated by 
dopamine, an abundance of evidence supports this 
contention. First, as noted above, although amphetamine 
has important actions on both dopamine and norepineph- 
fine neurons, norepinephrine appears to play an insig- 
nificant role in amphetamine-induced effects in the 
nigrostriatal system. Further, no changes in Prodyn 
peptides were observed in the hippocampus, a brain 
structure densely innervated by norepinephrine termi- 
nals. Moreover, similar changes in striatonigral Dyn 
A(1-8) have been reported following treatment with the 
direct acting dopamine agonist, apomorphine, which 
were reversed by the dopamine antagonist haloperido136. 
While not included in the present paper, we have 
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preliminary evidence suggesting that the effects of re- 
peated amphetamine administration on Prodyn peptides 
are attenuated by coadministration of haloperidol. The 
available evidence thus suggests that the effects of 
amphetamine on striatonigral prodynorphin peptides are 
indeed mediated by dopamine. 
In contrast to amphetamine, haloperidol alone had no 
significant effects on individual striatonigral Prodyn 
peptides, whether injected acutely, or repeatedly for 4 or 
15 days. These results are consistent with reports by 
Peterson and Robertson 48 and Li et al. 36, that repeated 
injections of haloperidol had no effects on Dyn A(1-8); 
however, they are at odds with reports by Quirion et al. 51 
and Tandon et al. 57, that repeated haloperidol injections 
dramatically altered striatonigral Prodyn peptides. The 
reason for the differences in the effect of haloperidol 
observed in these studies is presently unclear. Despite the 
lack of significant effects of haloperidol on individual 
peptides, however, this system was not entirely un- 
affected by treatment with the dopamine antagonist in 
the present study. Following 15 days treatment there was 
a change in the 'precursor-product'  relationship between 
Dyn A(1-17) and Dyn A(1-8): a significant dose- 
dependent increase in the Dyn A(1-8):Dyn A(1-17) 
ratio was observed in the striatum, which was paralleled 
in the substantia nigra. In addition, although not signifi- 
cant, there were suggestions of similar changes following 
acute or 4-day treatment with haloperidol. The changes, 
as would be expected, were opposite to those seen 
following acute or chronic treatment with amphetamine. 
These results suggest that haloperidol causes a subtle 
decrease in release and/or increase in processing of 
Prodyn peptides, such that the more processed products 
accumulate more rapidly than the intermediate peptides. 
Thus, while we were unable to replicate the significant 
effects of haloperidol on Prodyn peptides previously 
observed in our laboratory 57 or those seen by Quirion et 
al. 51, we found that blockade of dopamine receptors did 
indeed affect the striatonigral Prodyn system. 
The effects of amphetamine and haloperidol treatment 
on Prodyn peptides are in stark contrast to the effects of 
these drugs on the proenkephalin peptide MERGL. 
While acute or repeated injections of amphetamine 
caused dramatic effects on Prodyn peptides, there was no 
effect of amphetamine treatment on MERGL. In addi- 
tion, while haloperidol treatment had relatively subtle 
effects on Prodyn peptides, repeated administration of 
this drug caused dramatic increases in MERGL; previous 
studies have shown increases in enkephalin peptides, 
precursors and messenger RNA following haloperidol 
treatment 4'6"16"27"2s'41'44'58. Thus, whereas Prodyn pep- 
tides appear to be highly affected by increases in 
dopaminergic activity and little affected by decreases, the 
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opposite pattern appears to be true for proenkephalin 
peptides. These results indicate that there are distinct 
mechanisms involved in the regulation by dopamine of 
the two opioid peptide families in the striatum. These 
findings are consistent with suggestions that enkephalins 
and dynorphins may reside in different populations of 
neurons within the striatum 5'~s. The effects of dopamin- 
ergic drugs on both Prodyn and proenkephalin peptides 
can be contrasted with the effects of these compounds on 
another striatal peptide system, substance P. Striatonigral 
substance P is increased by dopamine agonists 2<s-~, but 
unlike Prodyn peptides, decreased by dopamine ant- 
agonists 2°'2~'2~. The latter dissociation between Prodyn 
peptides and substance P is very interesting in light of 
recent demonstrations that Prodyn peptides and sub- 
stance P may be colocalized in striatal cell bodies ~'3"5~. 
There are some interesting functional issues that 
should be discussed regarding these results. The present 
observation that Prodyn peptides may be released fol- 
lowing acute injections of amphetamine suggests that 
these transmitters might be involved in some of the 
behavioral consequences of acute amphetamine admin- 
istration. Indeed, the fact that several amphetamine- 
dependent behaviors are blocked by the opiate receptor 
antagonist naioxone suggests that endogenous opioids 
may mediate these behaviors. Of particular note are 
naloxone antagonism of the rewarding effects of amphet- 
amine, as determined by facilitation of self-stimulationt3" 
25.59 or by conditioned place preference s9, as well as 
naloxone blockade of amphetamine-stimulated locomo- 
tor behaviors, such as increased activity 23'24 and turning 
behavior m. These behaviors are of particular significance 
to the present study due to the demonstrated role of the 
striatum in their expression; evidence suggests that the 
rewarding effects and the locomotor stimulating effects of 
amphetamine are mediated by the ventral striatum (or 
nucleus accumbens; see refs. 15, 30, 63), while amphet- 
amine-dependent turning is mediated primarily by the 
dorsal striatum (or caudate-putamen; see ref. 31). In 
addition to the possible involvement in the acute effects 
of amphetamine, the changes in Prodyn peptides seen 
following repeated amphetamine suggests that these 
peptides might be involved in the behavioral manifesta- 
tions resulting from multiple injections of this drug. Two 
distinct syndromes are seen following repeated adminis- 
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